Endometrial hyperplasia and the risk of progression to carcinoma.
about
Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulationTransforming growth factor β signaling in uterine development and functionReactivation of codogenic endogenous retroviral (ERV) envelope genes in human endometrial carcinoma and prestages: Emergence of new molecular targetsOverexpression of erythropoietin-producing hepatocyte receptor B4 and ephrin-B2 is associated with estrogen receptor expression in endometrial adenocarcinoma.Eruptive inflamed seborrheic keratoses in the setting of endometrial adenocarcinoma.Uterine epithelial cell proliferation and endometrial hyperplasia: evidence from a mouse modelThe efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review.Mitochondrial DNA content and mass increase in progression from normal to hyperplastic to cancer endometrium.Estrogen and progesterone regulate p27kip1 levels via the ubiquitin-proteasome system: pathogenic and therapeutic implications for endometrial cancer.An estrogen-induced endometrial hyperplasia mouse model recapitulating human disease progression and genetic aberrations.PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factorsShort- and Long-Term Effects of Prenatal Exposure to Iron Oxide Nanoparticles: Influence of Surface Charge and Dose on Developmental and Reproductive Toxicity.Role of transvaginal ultrasonography in diagnosing endometrial hyperplasia in pre- and post-menopause women.LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: a randomized controlled trialInhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancerEmerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS).Life-style and metformin for the prevention of endometrial pathology in postmenopausal women.Association of endometrial hyperplasia and cancer with a history of gestational diabetes.Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.CTCF genetic alterations in endometrial carcinoma are pro-tumorigenic.Relation of metabolic syndrome with endometrial pathologies in patients with abnormal uterine bleeding.Depo-Provera Versus Norethisterone Acetate in Management of Endometrial Hyperplasia Without Atypia.Advances in endometrial cancer protein biomarkers for use in the clinic.The role of interleukin-1b and its antagonist (diacerein) in estradiol benzoate-induced endometrial hyperplasia and atypia in female rats.Molecular profiles of benign and (pre)malignant endometrial lesions.New classification system of endometrial hyperplasia WHO 2014 and its clinical implications.Could body mass index be an indicator for endometrial biopsy in premenopausal women with heavy menstrual bleeding?Expression of miRNAs and PTEN in endometrial specimens ranging from histologically normal to hyperplasia and endometrial adenocarcinoma.HOXB9 promotes endometrial cancer progression by targeting E2F3.
P2860
Q24200519-EFE2DA30-9EEC-4326-B22E-E574A9F66714Q26824939-968EF8B8-6044-47B8-94A6-4FB72D3E52EAQ30418097-772051E0-62EA-48F2-9EF6-38CAE392E02AQ33599430-DF9A3CB5-B562-4354-AF37-55441729D380Q33641223-2458F9F1-25D7-4E9A-A1B1-17FA5110D4AAQ33932553-527149E4-F2DA-4530-8838-BDABB00850B0Q34053682-8579FCD9-44A5-467D-B353-BC18AB62450CQ34296416-351CF71D-655B-457B-A2C3-5E76BF476B4DQ34430770-6CB16122-807E-4A37-B1D0-E39146AD7115Q35928907-2ADD22BE-4FDB-4254-83E7-78A645A2C760Q36235829-1D70E506-8B8E-4B76-9F92-2E682B52DDC7Q36404343-BE82B99D-C1C9-4B19-8E6A-98A4F55E6E14Q36423728-C4E4C65E-214D-4BEE-BD36-A780B74049C2Q36817480-6C680098-4ED3-46C6-9CC0-753AE084B083Q37240152-89618AB6-15F6-443E-A2FD-0B9E3844D335Q37946922-FF4240EA-AB77-4A3A-9275-34BFC39B1377Q38040433-695D53E8-F3AE-4CC9-98BC-E040F26753FBQ38675379-CA81E719-A9B5-4040-80A5-B751F3ACC77BQ38984243-5393E8D3-EDEE-4301-829C-8C9FA97AE8FAQ41073866-55E817C9-F837-4C27-880C-DBCA1832D1E1Q41580061-789E4EB9-6A16-436D-91FA-B2389311571AQ46974182-49E566AA-0698-442C-9D0C-3A48D2578CA4Q47355920-21451DA8-C1DB-4949-B181-0492BB31237AQ47826239-8295A472-F394-4515-9B1A-E051C50C2E1DQ51135997-004EC476-3894-433E-A7EE-A3EF5671D9CBQ52366406-E7B3A05B-0508-4442-88CE-47C3C0AC0FB6Q53170373-BA934B02-3CDB-43EC-902D-4747EA8944B9Q54302143-C3F9DAE9-C5CA-4071-BE25-860D775748C0Q55167079-2C545E62-663B-4D2A-9116-9CB39BD73F8A
P2860
Endometrial hyperplasia and the risk of progression to carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Endometrial hyperplasia and the risk of progression to carcinoma.
@en
Endometrial hyperplasia and the risk of progression to carcinoma.
@nl
type
label
Endometrial hyperplasia and the risk of progression to carcinoma.
@en
Endometrial hyperplasia and the risk of progression to carcinoma.
@nl
prefLabel
Endometrial hyperplasia and the risk of progression to carcinoma.
@en
Endometrial hyperplasia and the risk of progression to carcinoma.
@nl
P1433
P1476
Endometrial hyperplasia and the risk of progression to carcinoma.
@en
P2093
James V Lacey
Victoria M Chia
P356
10.1016/J.MATURITAS.2009.02.005
P577
2009-03-13T00:00:00Z